Marković, F.; Stjepanović, M.; Rančić, M.; Cekić, M.; Kontić, M.
Real-World Outcomes of First-Line Pembrolizumab Monotherapy in Metastatic NSCLC with High PD-L1 Expression (TPS ≥ 50%): A Multicenter Study from Serbia. Biomedicines 2025, 13, 1175.
https://doi.org/10.3390/biomedicines13051175
AMA Style
Marković F, Stjepanović M, Rančić M, Cekić M, Kontić M.
Real-World Outcomes of First-Line Pembrolizumab Monotherapy in Metastatic NSCLC with High PD-L1 Expression (TPS ≥ 50%): A Multicenter Study from Serbia. Biomedicines. 2025; 13(5):1175.
https://doi.org/10.3390/biomedicines13051175
Chicago/Turabian Style
Marković, Filip, Mihailo Stjepanović, Milan Rančić, Marina Cekić, and Milica Kontić.
2025. "Real-World Outcomes of First-Line Pembrolizumab Monotherapy in Metastatic NSCLC with High PD-L1 Expression (TPS ≥ 50%): A Multicenter Study from Serbia" Biomedicines 13, no. 5: 1175.
https://doi.org/10.3390/biomedicines13051175
APA Style
Marković, F., Stjepanović, M., Rančić, M., Cekić, M., & Kontić, M.
(2025). Real-World Outcomes of First-Line Pembrolizumab Monotherapy in Metastatic NSCLC with High PD-L1 Expression (TPS ≥ 50%): A Multicenter Study from Serbia. Biomedicines, 13(5), 1175.
https://doi.org/10.3390/biomedicines13051175